When monitoring a patient on methimazole (Tapazole), which tests are crucial?

The correct choice is based on the importance of monitoring specific laboratory values for a patient who is being treated with methimazole. Methimazole is an antithyroid medication commonly used to manage hyperthyroidism by inhibiting the synthesis of thyroid hormones. Given its mechanism of action and potential side effects, monitoring a complete blood count (CBC) and liver transaminases is crucial.

A CBC is essential because methimazole can cause hematological side effects, particularly agranulocytosis, which is a potentially serious condition characterized by a dangerously low white blood cell count. Regular monitoring can help identify this side effect early, allowing for timely intervention. Additionally, liver transaminases are monitored to assess for any liver function abnormalities, as liver toxicity can occur with methimazole use.

While monitoring total thyroxine (T4) levels is important in assessing the effectiveness of hyperthyroidism treatment, it is not specific to the adverse effects of methimazole itself. The other options, such as glycated hemoglobin, primarily assess diabetes management, and uric acid levels are not directly relevant to methimazole therapy. Therefore, the combination of CBC and liver transaminases provides a comprehensive safety profile for patients on this medication.